NCT07480525 Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
| NCT ID | NCT07480525 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University |
| Condition | Depression - Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-03-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression. This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity. 2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI). 3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4. 4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months. 5. Written informed consent obtained from the patient. Exclusion Criteria: 1. Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc.. 2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness; 3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury; 4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5. 5. Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation. 6. Have known allergies to escitalopram oxalate or its excipients. 7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy. 8. Have participated in another drug clinical trial within the past 3 months. 9. Have contraindications to MRI scanning, such as metal implants or claustrophobia. 10. Considered unsuitable for study participation by the investigators for any other reason.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07480525 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Depression - Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07480525 currently recruiting?
Yes, NCT07480525 is actively recruiting participants. Contact the research team at dryue@bjmu.edu.cn for enrollment information.
Where is the NCT07480525 trial being conducted?
This trial is being conducted at Beijing, China, Baoding, China, Shijiazhuang, China, Shenyang, China and 1 additional location.
Who is sponsoring the NCT07480525 clinical trial?
NCT07480525 is sponsored by Peking University. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.